A Phase Ib, Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Idarubicin and Cytarabine Induction and High-dose Cytarabine-based Consolidation Therapy in Adult Patients Less Than or Equal to 65 Years Old With Acute Myeloid Leukemia (AML)

Inclusion Criteria:

- Newly diagnosed adult patients = 65 years old with a cytopathologically confirmed
diagnosis of high-risk AML

- = 20% bone marrow blasts via bone marrow aspiration or biopsy

- The patient has not yet been treated for AML

- 1º or 2º AML patients with high-risk category features

- ECOG PS = 2

- Renal function and liver function limits.

Exclusion Criteria:

- Patient with a 'favorable' or 'better-risk' cytogenetic profile = t(15;17); t(8;21);
or inv(16) or t(16;16)

- Patient has clinical symptoms suggestive of CNS leukemia and/or CSF findings for CNS
leukemia

- Prior treatment with deacetylase inhibitors (DACi) including, panobinostat

- Impaired cardiac function

- Female patient who is pregnant or breast feeding

- Male patient who is not willing to use a barrier method of contraception

Other protocol-defined inclusion/exclusion criteria may apply